Oncolytics Biotech Operating Income 2011-2026 | ONCY

Operating profit (also called operating income or profit from core activities) is a financial metric that reflects a company's profit from its main operational activities before interest expenses and taxes are taken into account.

Formula

Operating profit = Revenue – Operating expenses

Features of the metric

Evaluates business efficiency
Shows how well the company controls its production and administrative costs.
Independent of financial structure
Excludes the impact of debt burden (interest) and taxes, allowing objective comparison of companies.
Main source for growth
High operating profit provides resources for investments, business expansion, and increased competitiveness.

If a company shows strong operating profit, it signals to investors that the core business is operating efficiently, even if net profit is temporarily reduced due to debt or tax burden.

Annual Operating Income Oncolytics Biotech

2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
-	-	-	-26.2 M	-25.5 M	-20.4 M	-17.3 M	-15.6 M	-15.3 M	-13.9 M	-	-	-	-

All numbers in CAD currency

Indicator range from annual reports

Maximum	Minimum	Average
-13.9 M	-26.2 M	-19.2 M

Operating Income of other stocks in the Biotechnology industry

Issuer	Operating Income	Price	% 24h	Market Cap	Country
MorphoSys AG MOR	-508 M	-	2.43 %	$ 254 M	Germany
ARCA biopharma ABIO	-88.1 M	-	1052.0 %	$ 415 M	USA
Acasti Pharma ACST	-16.7 M	-	4.01 %	$ 150 M	Canada
AC Immune SA ACIU	-79 M	$ 2.72	7.51 %	$ 229 M	Schweiz
Adverum Biotechnologies ADVM	-139 M	-	-	$ 86.2 M	USA
AgeX Therapeutics AGE	-9.89 M	-	-10.17 %	$ 12.2 K	USA
Aeglea BioTherapeutics AGLE	-210 M	-	-	$ 1.01 B	USA
AIkido Pharma AIKI	-11.5 M	-	1.93 %	$ 17.4 M	USA
argenx SE ARGX	-349 M	$ 840.28	1.7 %	$ 25 B	Niderland
Ascendis Pharma A/S ASND	-452 M	$ 234.99	0.02 %	$ 5 B	Danmark
Akero Therapeutics AKRO	-285 M	-	-	$ 3.67 B	USA
Biophytis SA BPTS	-26.8 M	-	-13.47 %	$ 169 M	France
Albireo Pharma ALBO	-123 M	-	-0.23 %	$ 916 M	USA
Atea Pharmaceuticals AVIR	-193 M	$ 4.65	1.31 %	$ 392 M	USA
Allena Pharmaceuticals ALNA	-47.6 M	-	3.16 %	$ 1.9 M	USA
AlloVir ALVR	-65.4 M	-	4.14 %	$ 49.1 M	USA
Midatech Pharma plc MTP	-7 M	-	-18.52 %	$ 27.3 M	Britain
Akouos AKUS	-86.8 M	-	0.23 %	$ 488 M	USA
BioVie BIVI	-18.1 M	$ 1.25	-	$ 1.85 M	USA
Ampio Pharmaceuticals AMPE	-33.3 M	-	-11.43 %	$ 502 K	USA
Applied Molecular Transport AMTI	-127 M	-	-	$ 10.1 M	USA
BioMarin Pharmaceutical BMRN	484 M	$ 62.62	-0.48 %	$ 11.9 B	USA
Acorda Therapeutics ACOR	-265 M	-	-24.86 %	$ 820 K	USA
Acer Therapeutics ACER	-24.6 M	-	2.71 %	$ 14 M	USA
Aravive ARAV	-70.8 M	-	-13.39 %	$ 1.45 M	USA
Capricor Therapeutics CAPR	-24.1 M	$ 27.91	0.14 %	$ 747 M	USA
CASI Pharmaceuticals CASI	-41.8 M	$ 0.8	5.68 %	$ 109 M	USA
Applied Genetic Technologies Corporation AGTC	-17.7 M	-	-	$ 26.5 M	USA
Avenue Therapeutics ATXI	-11.3 M	-	-52.27 %	$ 4.45 M	USA
Catalyst Biosciences CBIO	-67.2 M	$ 12.65	10.29 %	$ 833 M	USA
Axsome Therapeutics AXSM	-167 M	$ 169.95	-2.75 %	$ 8.45 B	USA
Ayala Pharmaceuticals AYLA	-37.5 M	-	-	$ 7.46 M	Israel
Alpine Immune Sciences ALPN	-58.1 M	-	-	$ 2.17 B	USA
BioDelivery Sciences International BDSI	37.1 M	-	-4.8 %	$ 255 M	USA
Aeterna Zentaris AEZS	-8.67 M	-	5.93 %	$ 314 M	Canada
BeiGene, Ltd. BGNE	-568 M	-	0.49 %	$ 251 B	Cayman-islands
Biogen BIIB	7.04 B	$ 195.13	-0.62 %	$ 28.6 B	USA
Cellectis S.A. CLLS	-131 M	$ 3.98	0.51 %	$ 116 M	France
Bellicum Pharmaceuticals BLCM	-27 M	-	-9.72 %	$ 5.89 M	USA
Baudax Bio BXRX	-56.8 M	-	0.59 %	$ 63 K	USA
Aptinyx APTX	-62.6 M	-	-39.0 %	$ 4.57 M	USA
Cellectar Biosciences CLRB	-39 M	$ 3.36	3.07 %	$ 41.1 M	USA